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A B S T R A C T
Designer biopolymers (DBPs) represent state of the art genetically engineered biomacromolecules
designed to condense plasmid DNA, and overcome intra- and extra- cellular barriers to gene delivery.
Three DBPs were synthesized, each with the tumor molecular targeting peptide-1 (TMTP-1) motif to
speciﬁcally target metastases. Each DBP was complexed with a pEGFP-N1 reporter plasmid to permit
physiochemical and biological assay analysis. Results indicated that two of the biopolymers (RMHT and
RM3GT) effectively condensed pEGFP-N1 into cationic nanoparticles <100 nm and were capable of
transfecting PC-3 metastatic prostate cancer cells. Conversely the anionic RMGT DBP nanoparticles could
not transfect PC-3 cells. RMHT and RM3GT nanoparticles were stable in the presence of serum and
protected the cargo from degradation. Additionally it was concluded that cell viability could recover post-
transfection with these DBPs, which were less toxic than the commercially available transfection reagent
Lipofectamine1 2000. With both DBPs, a higher transfection efﬁcacy was observed in PC-3 cells than in
the moderately metastatic, DU145, and normal, PNT2-C2, cell lines. Blocking of the TMTP-1 receptors
inhibited gene transfer indicating internalization via this receptor. In conclusion RMHT and RM3GT are
fully functional DBPs that address major obstacles to gene delivery and target metastatic cells expressing
the TMTP-1 receptor.
ã 2016 Elsevier B.V. All rights reserved.
1. Introduction
It has long been anticipated that gene therapy will become a
revolutionary technology for the treatment of metastatic cancers.
However, in order to meet this expectation, innovative delivery
systems are required. These gene delivery systems must protect
the cargo, overcome an array of intra- and extra- cellular barriers,
confer a targeting capability, release the cargo and have a limited
inherent toxicity (McCrudden and McCarthy, 2013).
Various gene delivery strategies overcome many of these
hurdles and have therefore emerged to prominence in the ﬁeld,
however they each have inherent limitations. Viral vectors exhibit
immunogenicity and toxicity concerns, lipoplexes have reproduc-
ibility issues and toxicity concerns, and polyplexes have problem-
atic biocompatibilities and low transfection efﬁcacies (Pack et al.,
2005; Zhang et al., 2012). An appealing alternative utilizes
biomimetics that are capable of interacting and shuttling nucleic
acids in tunable and targeted virus-like nanoparticles (Unzueta
et al., 2014). Protein based biomimetics are of particular interest as
they are fully biocompatible and biodegradable. Furthermore
protein based vectors are customizable due to the broad spectrum
of moieties available for synthesis (Seow and George, 2011).
One such platform involves genetically engineering highly
cationic biopolymers with tandem repeating units through an
Escherichia coli expression system (Hateﬁ et al., 2006). This
manufacturing process utilizes a one-step genetic engineering
approach and permits the design of vector architecture at the
molecular level. The method removes the necessity for numerous
conjugation/puriﬁcation steps, consequently reducing the com-
plexity of synthesis (Karjoo et al., 2013). Numerous intricate non-
viral gene delivery systems, namely Designer Biopolymers (DBPs),
have been developed using genetic engineering technology
(Canine et al., 2011; McCarthy et al., 2011; Wang et al., 2009).
DBPs are based on a one-domain-one-function concept, with each
bio-inspired peptide domain working in concert to successfully
deliver nucleic acids to a target cell population. It has previously
been demonstrated that DBPs form spontaneously self-assembling
nanoplexes with plasmid DNA (pDNA), exhibit a low-toxicity, and* Corresponding author. Fax: +44 2890 247794.
E-mail address: h.mccarthy@qub.ac.uk (H.O. McCarthy).
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speciﬁcally target cell lines of interest. Cell lines that have been
targeted include ZR-75-1 breast cancer cells and SK-OV-3Her2-
positive ovarian cancer cells (Canine et al., 2011; Wang et al., 2009).
In addition DBPs have mediated efﬁcient gene transfer of suicide
genes, including inducible nitric oxide synthase (iNOS), thymidine
kinase (TK) and tumour necrosis factor-related apoptosis-inducing
ligands (TRAIL), to these aforementioned cancer cell lines
(Mangipudi et al., 2009; McCarthy et al., 2011; Wang et al., 2009).
Despite progress in molecular therapeutics the majority of
cancer-related mortalities are the consequence of distant metas-
tases rather than the primary tumors. For example, there are over
40,000 men diagnosed annually with prostate cancer (PCa) in the
United Kingdom (UK), of which a third develop a metastatic and
castration-resistant prostate cancer (mCRPC) with an associated
survival<19 months (Cancer Research, 2015; Prostate Caner, 2015).
For these patients the outlook is poor because CRPC tumours are
both radio- and chemo- resistant, exhibit a distinct bone tropism
with treatment options that are mainly palliative. Therefore there
is a desperate unmet need for alternative gene delivery vehicles
capable of systemically targeting CRPC.
Herein, we report on three DBPs for targeted gene transfer to
metastatic PCa, principally examining their physiochemical
characteristics and activity in a range of metastatic PCa cell lines.
Each platform; RMGT, RM3GT, and RMHT (Fig. 1), was genetically
engineered and contains moieties to overcome speciﬁc barriers to
gene delivery. Each DBP has a nuclear localization signal (NLS)
known as R, a DNA condensing motif (DCM) known as M, an
endosomal disruption motif (EDM) known as G, and a targeting
peptide (TP) known as T for site speciﬁcity. The rationale for
examining multiple DBPs is that certain moieties could behave
somewhat unpredictably and interfere with the three-dimensional
functionality of a vector, impacting upon speciﬁc gene transfer
efﬁciency.
The NLS, DCM, and TP sequences are identical for each DBP and
could be considered the base of each vector. The NLS, Rev, sequence
was adopted from the human immunodeﬁciency virus type-1 and
facilitates microtubule-assisted transport to the nucleus (Cochrane
et al., 1990). The highly cationic DCM, m peptide was derived from
the adenovirus and invokes charge-charge interactions with DNA
resulting in encapsulation into 80–110 nm-sized particles (Keller
et al., 2002). The TP, tumor molecular targeting peptide-1 (TMTP-
1), was identiﬁed using the FliTrx bacterial peptide display system
and binds to highly metastatic tumour cell lines with an afﬁnity for
micro-metastases (Yang et al., 2008).
In addition RMGT and RM3GT are equipped with GALA, a pH-
dependent amphipathic EDM, which facilitates endosomal escape
(Nicol and Szoka, 2004). RM3GT contains three repeating units of m
as it was speculated that GALA’s anionic nature might reduce the
overall charge of the nanoplex and prevent efﬁcient gene transfer.
Finally the EDM in RMHT is a pH-sensitive histidine-rich fusogenic
H5WYG peptide derived from the N-terminal segment of the HA-
2 subunit of the inﬂuenza virus. H5WYG confers endosomal
disruption upon protonation of the histidyl imidazole rings
interspersed throughout its sequence (Midoux et al., 1998).
We hypothesize that the DBPs multiple functional domains will
condense pDNA into non-toxic nanoparticles, protect DNA from
serum endonuclease directed degradation, target metastatic PCa,
internalize via receptor-mediated endocytosis, disrupt endosomal
Fig. 1. (a) Schematic representation of the designer biopolymers (DBPs) (b) RMGT, (c) RMHT, and (d) RM3GT. Each DBP is composed of a DNA condensing motif (DCM) to
condense plasmid DNA—yellow, a TMTP-1 targeting peptide (TP) for speciﬁcity—green, an endosomal disruption motif (EDM)—grey, and a nuclear localisation signal motif
(NLS)—red. A spacer sequence to confer ﬂexibility was also incorporated before the TMTP-1. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
J.W. McBride et al. / International Journal of Pharmaceutics 500 (2016) 144–153 145
membranes, and exploit nuclear translocation via microtubules to
mediate gene expression.
2. Materials and methods
2.1. Materials and cell lines
RMHT, RMGT, and RM3GT encoding nucleic acid sequences were
synthesized and subcloned, by Genscript (NJ, USA), into a pET21b
(+) expression vector (Merck, UK) under control of a T7 promoter. E.
coli BL21(DE3) pLysS competent cells were purchased from
Novagen, UK, and Circlegrow from MP Biomedical, UK. Isopropyl
b-D-1-thiogalactopyranoside (IPTG), Na2HPO4, Guanidine HCl,
imidazole, glycrol, bis-tris propane, sodium chloride, ethidium
bromide, Triton-X and sodium dodecyl sulphate (SDS) were
procured from Sigma–Aldrich, UK. Tris–HCl, 10% Bis-Tris gels
and SeeBlue Plus2 Pre-stained Standard for SDS-PAGE, 1 Kb Plus
DNA ladder, and Lipofectamine 2000 were purchased from
Invitrogen, UK. The reagents for confocal microscopy; Hoechst
nuclear stain, Fluorescein (FITC)-phalloidin and ProLong Gold
Antifade Reagent were purchased from Life Technologies, UK, apart
from the Cy-3 ﬂuorophore which was obtained from Mirus, USA.
Protease inhibitor cocktail 7 was supplied by Calbiochem, UK,
EDTA free protease inhibitor tablets and WST-1 reagent from
Roche, UK, Ni-NTA resin from Qiagen, UK, Sephadex G25 medium
from GE Healthcare, UK, Bio-Rad Assay Reagent from BioRad, USA,
and Agarose from Bioline, UK.
PC-3 and DU145 prostate cancer cells were purchases from
American Type Culture Collection (ATCC) (Manassa, VA) whereas
PNT2-C2 cells were kindly donated by Prof Norman Maitland at the
University of York. Cells were maintained as monolayers in Roswell
Park Memorial institute (RPMI) medium (Invitrogen, UK), 10%
foetal calf serum (PAA, UK), at 37 C, 5% CO2.
2.2. Production of recombinant DBPs
The expression vectors were transformed into BL21(DE3) pLysS
competent cells (Novagen, UK) as per the manufacturer’s
instructions. Each vector contained a hexahistidine tag to facilitate
Ni-NTA agarose afﬁnity chromatography. 200 ml starter cultures,
containing 50 mg/ml ampicillin, were grown in LB media overnight
at 37 C. The LB was used to inoculate 1 L of Circlegrow medium,
containing 50 mg/ml ampicillin, and incubated in an orbital shaker
at 30 C until the absorbance reached 0.8–1.2 (600 nm). Subse-
quently 0.4 mM (IPTG) was added to induce protein expression.
After 6 h cells were harvested by centrifugation at 4000  g for
15 min, 4 C, and then pellets were frozen at 20 C until required.
The pellet was resuspended in 25 ml of lysis buffer (100 mM
Na2HPO4, 10 mM Tris–HCl, 6 M Guanidine HCl titrated to pH 8,
150 ml protease inhibitor cocktail 7, and 1.5 EDTA free protease
inhibitor tablets. A further 50 ml of lysis buffer was added to the
resuspended pellet and agitated for 1 h prior to centrifugation for
1 h at 4000  g. The supernatant was adjusted to 10 mM imidazole,
and 1.8 ml of equilibrated Ni-NTA resin was added then rocked for
1 h at 30 rocks/min. Following centrifugation at 4000  g for 3 min
the supernatant was discarded and resin was loaded onto a
0.8  4 ml PolyPrep chromatography column (BioRad, UK) and
washed with 20 ml of wash buffer consisting of lysis buffer, 10%
glycerol, 0.5 EDTA free protease inhibitor tablets, and imidazole,
titrated to pH 8. Various imidazole concentrations were tested to
identify the binding afﬁnity of each DBP and thus achieve optimal
puriﬁcation: RMGT, 20 mM; RMHT, 25 mM; and RM3GT, 25 mM.
DBPs were eluted using a buffer consisting of 4 M guanidine HCl,
10 mM Tris-HCl, and 250 mM imidazole titrated to pH 8. DBP-rich
fractions were collected in 500 mL volumes. Sample purity and
expression was veriﬁed using SDS-PAGE against a pre-stained
protein ladder and samples were stored in 50% glycerol, 20 C.
2.3. Desalting and quantiﬁcation of DBPs
The puriﬁed protein was desalted through an equilibrated
Sephadex G25 medium contained in a 10 ml polypropylene column
(BioRad, USA). On the day of experiment the column was ﬁrst
equilibrated with 20 ml BTP buffer (10 mM bis tris propane and
5 mM sodium chloride titrated to pH 7). Then a DBP-rich fraction
was added to the column and once elution ceased 5 ml BTP buffer
was added. All ﬂow through was collected as 1 ml fractions and
immediately stored on ice. The concentration of the desalted
solution was quantiﬁed using a Bradford assay using Bio-Rad Assay
Reagent and read at 595 nm on a Nanodrop 2000 spectrophotom-
eter (Thermoscientiﬁc, UK).
2.4. Preparation of DBP/pDNA nanoparticles
The quantity of DBP protein to mg of DNA required for a given N:
P ratio (the molar ratio of nitrogen atoms in the polypeptide to
negative charges of the pDNA phosphate backbone) was calculat-
ed. SDS-PAGE revealed that dimers were predominantly puriﬁed,
due to disulﬁde bond formation between cysteine residues, and
therefore the dimer molecular weight was used in all subsequent
experiments. The two constituents, DNA and DBP, were mixed in
water and incubated for 30 min at room temperature before use.
2.5. Gel retardation assay
A gel retardation assay was employed to analyze the ability of
each DBP to neutralize the negative charge of the plasmid DNA
(pEGFP-N1). Samples at a range of N:P ratios 1–10, and DNA ladder,
were run on a 1% w/v agarose gel, 0.5 mg/ml ethidium bromide, for
40 min at 100 V. The gel was visualized using a UV transilluminator
(UVP, USA). Resulting images are representative of three indepen-
dent studies.
2.6. Particle size and charge analysis
DBP/pEGFP-N1 nanoparticles were prepared at a range of N:P
ratios using 1 mg of DNA. Nanoparticles were diluted in 1 ml of
molecular grade water in a polystyrene cuvette (Sarstedt,
Leicester). The mean hydrodynamic particle size was determined
using Dynamic Light Scattering (DLS) with the Malvern Nano
Zetasizer and DTS Software (Malvern Instruments, UK). Zeta
potential was analyzed using a foldable capillary cell (Sarstedt,
Leicester). The data was reported as the mean  SEM, with an n = 3.
2.7. Cell transfection studies
PC-3, DU145, and PNT2-C2 cell lines were seeded at cell
densities of 2.25 104, 2.50  104, and 3.50  104 cells/well,
respectively, into 96 well plates (VWR, UK). Cells were conditioned
for 2 h in Opti-MEM serum free media and subsequently trans-
fected with DBP/pEGFP-N1 at various N:P ratios, N:P 8–12
(equivalent to 1 mg of pDNA). After 4 h the media was replaced
with serum supplemented culture media. Green ﬂuorescent
protein (GFP) expression was visualized using a Nikon Eclipse
TE300 epiﬂuorescent microscope (Nikon, USA) 72 h post-transfec-
tion. Green ﬂuorescence was quantiﬁed using the FACS caliber
system (BD Biosciences, UK). Data was analyzed with Cyﬂogic
software (http://cyﬂogic.software.informer.com/) and ﬂuorescent
shift was calculated with 4% gating. Data was reported as
mean  SEM, n = 3.
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2.8. Confocal microscopy
pDNA was ﬂuorescently labeled with a Cy-3 ﬂuorophore (Mirus,
USA) per the manufacturer’s instructions. PC-3 cells, 10  104, were
seeded in a 24-well plate and incubated in serum supplemented
RPMI 1640 media for 24 h. Cells were conditioned for 2 h in Opti-
MEM serum free media and subsequently transfected with RMHT/
cy-3-pDNA at N:P 10 (equivalent to 1 mg of pDNA). After 4 h the
media was replaced with serum supplemented culture media. 48 h
post transfection cells were ﬁxed and permeabilized with 4%
formaldehyde and 0.1% Triton-X for 20 min. Subsequently, cells
were stained with 0.2 mg/ml Hoechst nuclear stain, and Fluores-
cein (FITC)-phalloidin for 15 min. Finally cells were treated with
ProLong Gold Antifade Reagent. Images were captured with a TCS
SP8 confocal microscope (Leica, UK) and analyzed using LAS AF Lite
Software (Leica, UK).
2.9. Cell viability study
PC-3 cells, 2.25 104, were seeded in a 96-well plate and
incubated in serum supplemented RPMI 1640 media for 24 h. Cells
were conditioned for 2 h in Opti-MEM serum free media and
subsequently transfected with DBP/pEGFP-N1 at N:P 10 (equiva-
lent to 1 mg of pDNA). After 4 h the media was replaced with serum
supplemented culture media. Lipofectamine 2000/pEGFP-
N1 nanoparticles, 1 mg of DNA, was used as a positive control
and produced per the manufacturer’s instructions. Cells were
incubated at 37 C 5% CO2, for 24 and 48 h time points before WST-
1 reagent was added to each well. Following a 4 h incubation at
37 C, the absorbance at 440 nm, was measured using an EL808 96-
well plate reader (Biotek, UK). Cell viability was normalized against
untreated cells that were deﬁned as 100% viable. The data are
reported as the mean of each condition SEM, n = 3.
2.10. Serum stability study
Two sets of DBP/pEGFP-N1 complexes, N:P 10, were incubated
for 1 h and 6 h at 37 C in the presence and absence of 10% fetal
bovine serum. Subsequently, 10% SDS (v/v) was added, for 10 min,
to one set of samples to decomplex the nanoparticles enabling
analysis of DNA integrity. All samples were run for 1 h on a 1% w/v
agarose gel containing 0.5 mg/ml ethidium bromide in a Tris-
acetate running buffer, and visualized using a UV transilluminator
(UVP, USA). A 1 Kb Plus DNA ladder was used as a marker. Image is
the representative image of three independent studies.
2.11. Competitive inhibitor study
A range of free TMTP-1 peptide concentrations were ﬁrst added
to PC-3 cells in Opti-MEM and subsequently DBP/pEGFP-
N1 complexes, N:P 10, were added as per the Cell transfection
studies. Opti-MEM was replaced after 2 h and analysis was carried
out as per Cell transfection studies after 48 h. Data was reported as
mean  SEM, n = 3.
Fig. 2. SDS-PAGE of puriﬁed designer biopolymer (DBP) fractions. Samples were run at 200 V on a 10% Bis-Tris gel against a 1Kb+ ladder. (a) RMGT, washed using 20 mM
imidazole, in which a 10.8 and 21.8 kDa monomer and dimer were resolved. (b) RMHT, washed with 25 mM of imidazole in which a clean 22.8 kDa dimer was eluted. (c)
RM3GT, 25 mM imidazole wash step, in which the 34.5 kDa protein was resolved (d) Protein concentration of each fraction collected, estimated using a Bradford assay. Results
displayed as mean  SEM, n = 3.
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2.12. Statistical analysis
The statistical data for the cytotoxicity assay was generated
using the one-way ANOVA Tukey post-hoc test for multiple
comparisons when investigating a single time point, and the
Student’st-test was used for toxicity comparisons of each DBP
across time points. The one-way ANOVA Tukey post-hoc test was
also implemented when comparing the transfection efﬁcacy across
cell lines and in the inhibitor study. Graphpad Prism (Graphpad
Software 4,0, Inc., Sand Diego, CA, USA) was used for all statistical
analysis.
3. Results and discussion
A model gene delivery vehicle should protect its nucleic acid
cargo while speciﬁcally delivering its payload without cytotoxicity.
Furthermore, for clinical application, it is extremely favorable if
these vectors are cost-effective and reproducible, with a simple
synthesis and puriﬁcation method that is amenable to scale-up
(Allen and Cullis, 2013; Lammers et al., 2012). DBP’s have
previously been shown to form self-assembling nanoplexes
capable of targeted gene delivery coupled with low-toxicity
(Canine et al., 2011; Wang et al., 2009). Additionally, the
manufacturing process utilizes a one-step genetic engineering
approach, which removes the necessity for numerous conjugation/
puriﬁcation steps, consequently reducing variability, synthesis
complexity, and cost (Canine et al., 2011; Ghandehari and Hateﬁ,
2010; Karjoo et al., 2013).
Here, three DBPs (Fig. 1) were manufactured by recombinant
engineering technology. Each DBP was comprised of four
functional peptide motifs of diverse biological origin, each with
a speciﬁc role in overcoming intra- and extra- cellular barriers, and
was synthesized as a single chain fusion biopolymer. The base
moieties were a Rev NLS followed by m DCM, at the N-terminus,
and a TMTP-1 TP positioned at the C-terminus. Both RMGT and
RM3GT contained the pH responsive fusogenic peptide GALA as the
EDM, while the latter contained three repeating units of m. The
only difference between RMHT and RMGT is that the m EDM was
replaced with H5WYG. Each construct was characterized with a
range of physicochemical and biological assays to determine their
functionality and target speciﬁcity to the metastatic cancer cell line
PC-3.
Each DBP was synthesized and puriﬁed using recombinant DNA
technology under stringent conditions. Expression vectors that
encode the his-tagged DBP sequences were transformed into BL21
(DE3) pLysS E. coli and vector synthesis was induced with 0.4 mM
IPTG before subsequent puriﬁcation via nickel bead afﬁnity
chromatography. Low concentrations of imidazole were used
during the puriﬁcation process to displace non-speciﬁc protein-
nickel interactions. Imidazole competes for nickel binding with
non-speciﬁc proteins that contain histidine, as this amino acid has
imidazole functional groups. The same mechanism is exploited to
Fig. 3. (a) Agarose gel retardation assay analysing a range of designer biopolymers (DBPs) ((i) RMGT, (ii) RMHT, and (iii) RM3GT) ability to neutralize pEGFP-N1 over a range of
nitrogen (DBP): phosphate (DNA) (N:P) ratios. Nanoparticles were prepared using 1 mg DNA and incubated for 30 min before loading onto the agarose gel. L: 1 Kb Plus ladder;
C: DNA only; 1–10: N:P ratios. Images representative of three independent repeats. (b) Mean hydrodynamic size and zeta potential of designer biopolymers (DBPs) ((i) RMGT,
(ii) RMHT, and (iii) RM3GT) complexed with DNA over a range of nitrogen (DBP): phosphate (DNA) (N:P) ratios. DBP nanoparticles were prepared with 1 mg of pEGFP-N1 and
incubated for 30 min prior to analysis with the Malvern Zetasizer Nano. Results displayed as mean  SEM, n = 3. A minimum of 15 measurements were performed for each
experiment.
148 J.W. McBride et al. / International Journal of Pharmaceutics 500 (2016) 144–153
resolve the pure DBP, when a high concentration of imidazole is
required to displace its polyhistidine-tag. Each DBP therefore has a
nickel afﬁnity threshold. Ranges of imidazole concentrations were
used to identify this threshold and eliminate as much non-speciﬁc
protein as feasibly possible, critically without compromising DBP
yield.
Expression and purity was veriﬁed using SDS-PAGE (Fig. 2a–c).
Puriﬁcation of 1 L of recombinant E. coli produced ﬁve 500 ml
aliquots of DBP protein. The greatest yield for each DBP was either
in fraction 2 or 3 and commonly contained approximately 2 mg/ml
(Fig. 2d). This yield is comparable to previous studies using
recombinant methods (Mangipudi et al., 2009). Before
characterization, DBP fractions were desalted using a Sephadex
column. The removal of salt ions will reduce the possibility of salt
bridge formation in between the nanoparticles and thus prevent
aggregation (Karjoo et al., 2013; Nouri et al., 2013).
The ability of each DBP to condense pEGFP-N1 into nano-
particles was analyzed. A gel retardation assay was used to
ascertain at which N:P ratio pDNA neutralization occurred, while
dynamic light scattering was used to determine hydrodynamic
particle size. The gel retardation assay revealed that RMGT did not
appear to neutralize pEGFP-N1. This was not unexpected, as the
number of positively and negatively charged residues within the
vector will neutralize itself. Indeed, regardless of the N:P ratio
Fig. 4. (a) Evaluation of the optimal nitrogen (DBP): phosphate (DNA) (N: P) ratios for PC-3 cell transfection with the designer biopolymers (DBPs) as analyzed using (i)
ﬂuorescent microscopy and (ii) transfection efﬁcacy 48 h post-transfection as measured by ﬂow cytometry. Results displayed as mean  SEM, n = 3. (b) Confocal microscopy of
phalloidin stained (green—actin) and Hoechst stained (blue—nucleus) PC-3 cells transfected with RMHT:Cy-3 (red) labelledlabeled DNA. Viewed using a Leica confocal
platform. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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pDNA freely migrated down the gel, due to its negative charge,
identical to the DNA only control (Fig. 3a. i). RMGT/pEGFP-
N1 formed nanoparticles across a range of N:P ratios (N:P
10 hydrodynamic size of 419  77 nm). However, zeta potential
analysis revealed that the RMGT/pEGFP-N1 particles have an
overall negative zeta potential (e.g.,–24 1 mV at N:P 8) thus
explaining the migration down the agarose gel (Fig. 3b. i). RMHT
and RM3GT inhibited pDNA migration, and therefore neutralized
the negative charges of the phosphate backbone at N:P 4 and 2,
respectively (Fig. 3a. ii–iii). RMHT/pEGFP-N1 nanoparticles exhib-
ited a hydrodynamic diameter under 150 nm from N:P 7 and above
(Fig. 3B. ii). RM3GT formed nanoparticles under 150 nm from N:P 8
(Fig. 3. B. iii). Charge analysis revealed that the RMHT and RM3GT
nanoparticles are cationic with a surface charge of over 20 mV at a
range of N:P ratios. These ﬁndings indicate that RM3GT and RMHT
formed nanoparticles via electrostatic interactions—covalent with
the DNA cargo forming cationic nanoparticles.
The functionality of the DCM is to neutralize and condense DNA,
leaving the other motifs to fulﬁll their roles. Arginine is the optimal
amino acid for DNA condensation, doing so in milliseconds (Malim
et al., 1989; Murray et al., 2001). The arginine rich, m, DCM in all
three DBPs aided in DNA interaction, though with varying degrees
of condensation. These results indicate that DNA neutralization
and nanoparticle formation can be achieved by increasing the
content of cationic moieties, or by substituting anionic moieties. To
elaborate, compared to RMGT, RM3GT contained two additional
tandem m moieties and therefore 9 additional cationic arginine
residues for DNA condensation. These additions have resulted in a
highly positive nanoparticle surface charge with nanoparticles
<100 nm in size. On the other hand, a similar result was garnered
through EDM substitution of GALA, which contains seven anionic
glutamic acid residues, with H5WYG, which contains no negatively
charged residues.
Next the DBPs were analyzed for their ability to transfect a
conventional androgen insensitive metastatic PCa cell line, PC-3.
DBP/pEGFP-N1 nanoparticles were assessed at a range of N:P ratios
to determine which ratio had the maximum efﬁcacy for each
formulation. Negligible GFP expression was observed with RMGT
via qualitative ﬂuorescent microscopy, while RMHT and RM3GT
successfully facilitated transgene expression (Fig. 4). Confocal
microscopy demonstrates that the Cy-3 labeled DNA is delivered
into the cytoplasm and the nucleus of PC-3 cells following
transfection with RMHT (Fig. 4 b). It is not surprising that both
RMHT and RM3GT transfected cells as it is widely accepted that
targeted cationic nanoparticles with sizes of less than 200 nm are
appropriate for cellular entry via receptor-mediated endocytosis
through clathrin-coated vesicles (Rejman et al., 2004). RMHT and
RM3GT transfected optimally at N:P 10 and N:P 11 respectively.
RMHT facilitated the highest and most consistent gene delivery of
19%  3.3 at N:P 10.
Fusogenic pH-responsive EDMs are necessary to facilitate
escape from the endosomal department into the cytosol. In a
previous EDM functionality study, identical single chain multi-
functional tripartite biopolymers were synthesized with different
EDMs, it was discovered that GALA was more efﬁcient than H5WYG
(Nouri et al., 2013). The results of this study indicate that H5WYG is
optimal; however, the surrounding vector sequences must be
considered as diverse complex interactions may inﬂuence gene
Fig. 5. Further analysis of the designer biopolymers (DBPs) RMHT and RM3GT. (a) Agarose gel illustrating the stability of (i) RMHT/pEGFP-N1 and (ii) RM3GT/pEGFP-N1 at N:P
10. Representative image of three independent experiments. L: 1Kb Plus ladder; C: DNA only; 1: DBP/DNA complexes in the absence of serum for a 1 h incubation; 2: DBP/DNA
complexes in the absence of serum for a 6 h incubation; 3: DBP/DNA complexes incubated with serum for 1 h; 4: DBP/DNA complexes incubated with serum for 6 h; 5:
Decomplexed DBP/DNA following 1 h incubation in serum; 6: Decomplexed DBP/DNA following 6 h incubation in serum; 7: DNA incubated with serum for 10 min. (iii) Control
detailing interaction of serum incubated with SDS for 10 min. (b) Cell viability, assessed by WST-1 assay 24 and 48 h post-transfection, of PC-3 cells transfected with RMHT/
pEGFP-N1 and RM3GT/pEGFP-N1, N:P 10. All results displayed as mean  SEM, n = 3. ***P < 0.0005, **P < 0.01.
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transfer. For example RMHT and RM3GT are not directly compara-
ble with each other as the latter has additional DCMs that will
impact on the overall transfection efﬁcacy.
In the next step the optimal ratio, N:P 10, of RMHT/pEGFP-
N1 and RM3GT/pEGP-N1, for transfection were examined in a
serum stability study and cytotoxicity study. A serum stability
study is critical as upon intravenous administration of a
nanoparticle formulation the most abundant blood plasma
proteins adsorb to the surface, forming protein corona, which
are replaced over time by proteins that have a higher afﬁnity via
the Vroman's effect (Vroman et al., 1980). These complex
interactions can lead to pharmacokinetic complications and
presentation to macrophages (Wagstaff et al., 2007). Secondly
exposed pDNA is rapidly degraded by serum endonucleases so it is
important that the DBPs efﬁciently protect their cargo.
RMHT and RM3GT nanoparticles were stable for at least 6 h at
37 C, in the presence of 10% serum (Fig. 5a). Furthermore when the
nanoparticles were decomplexed with SDS to verify if the pDNA
remained intact, the supercoiled isoform was unaltered, suggest-
ing it was not susceptible to serum endonuclease degradation. The
serum stability study also revealed that RMHT/pEGFP-N1 and
RM3GT/pEGFP-N1 nanoparticles did not interact with the serum, as
a serum band is visible at 3 kb. Comparatively, after 10 min
unprotected DNA exposed to serum began to degrade as
demonstrated by the smear on the electrophoretic gel. The ‘smile’
band at approximately 1 kb in lanes containing FCS and SDS is an
interaction between the two and is not due to interaction with the
pDNA or DBP (Fig. 5a. iii). This evaluation suggests that the
nanoparticles are stable, and that the DBP's protect the payload
from endonucleases, which is essential if it is to reach the target
destination.
The cytotoxicity study revealed that both RMHT and RM3GT
DBPs impacted on PC-3 cell viability. After 24 h the toxicity proﬁle
was similar to, but not as potent as, the commercially available
Lipofectamine 2000 (Fig. 5b). Many liposome formulations, for
example Lipofectamine 2000, impact on cellular processes
including cell cycle control, apoptosis, cellular metabolism, and
contribute to cytokine production, pore formation, and cell lysis
(Dokka et al., 2000; Fiszer-Kierzkowska et al., 2011; Nguyen et al.,
2007). The apparent potent toxicity with RMGT and RM3GT could
be due to sequence similarities shared with antimicrobial peptides,
as they are also comprised of cationic and lipophilic residues that
bind to anionic cell membrane proteins subsequently reducing
their integrity (Hancock, 1997; Hilchie et al., 2011). Similar to the
ﬁndings here, it has been demonstrated that the H5WYG EDM in
biopolymeric system reduced viability by approximately 50% in
SKOV-3 cells when analyzed 24 h post-transfection and that a
GALA EDM causes nominal toxicity (Nouri et al., 2013). However,
Fig. 6. Evaluation of the targeting peptide functionality of RMHT/pEGFP-N1 and RM3GT/pEGFP-N1 at nitrogen (DBP): phosphate (DNA) (N: P) ratio 10 by (a) transfecting a
range of cell lines and (b) using free targeting peptide, at various concentrations, as a competitive inhibitor. In each case (a.i–b.i) ﬂuorescent microscopic images were captured
and (a.ii–b.ii) transfection efﬁcacy was determined via ﬂow cytometry 48 h post-transfection. Results displayed as mean  SEM, n = 3. *P < 0.05, **P < 0.005, ****P < 0.00005.
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given the structural differences between all of these DBPs it is
virtually impossible to compare one against the other, for example
it has been reported that H5WYG is non-toxic as it confers a neutral
charge at physiological pH, and therefore inhibits membrane
interaction or internalization, ergo toxicity (Midoux et al., 1998).
Despite apparent toxicity an increase in cell viability was
observed 48 h post-transfection with RMHT (p < 0.01) and RM3GT,
indicating cell recovery, whereas liposomal treated cells did not
recover. Furthermore both biopolymers had signiﬁcantly greater
cell viability at 48 h compared to Lipofectamine 2000 (p < 0.0005).
It is possible that following transfection cellular stress results in a
senescence or decrease in metabolic rate before recovering to
normal cell cycle (Mello de Queiroz et al., 2012). Ideally a potent,
speciﬁc, and non-toxic systemic gene delivery system is required.
Current nanoparticle formulations have been reported as signiﬁ-
cantly more cytotoxic than naked pDNA (Nguyen et al., 2007),
though the latter is fundamentally ﬂawed due to gene transfer
inefﬁciency and a likelihood of degradation (Fig. 5). Here, although
decreased cell viability was observed with RMHT/pEGFP-N1, N:P
10, and RM3GT/pEGFP-N1, N:P 10, both formulations aided in
transfection of PC-3 cells over pDNA, with RMHT nanoparticles
exhibiting a 19%  3.3 transfection efﬁcacy (Fig. 4a. ii).
Targeting speciﬁcity is crucial for the application of nano-
medicine to metastatic disease, as many tumors arise at inoperable
distant sites. The pentamer TMTP-1 sequence has an afﬁnity for
such micro-metastasis (Yang et al., 2008). Furthermore TMTP-1 has
been incorporated in polymeric systems assisting in tumor-
homing imaging and targeting of anti-tumor peptides both in
vitro and in mouse models (Li et al., 2015; Liu et al., 2012; Ma et al.,
2012). To assess whether metastatic targeting was retained when
the TP was included in the RMHT and RM3GT vector design two
experiments were completed. First the transfection efﬁcacy in
three PCa cell lines was examined (Fig. 6a); namely PC-3, DU145,
and PNT2-C2 cells, which are highly metastatic, moderately
metastatic, and a prostate normal cell line.
Selective gene transfer was observed with RMHT/pEGFP-
N1 and RM3GT/pEGFP-N1, N:P 10, as the expression in PC-3s
was signiﬁcantly greater than DU-145 and PNT2-C2 (p < 0.05). The
higher transfection efﬁcacy in PC-3 cells is most likely attributed an
increase in TP ligand receptors available for internalization. A
similar observation has been made with a DBP containing a HER2
targeting motif (Wang et al., 2009). Secondly, an inhibition assay
was performed to demonstrate that the nanoparticles were
internalized via the receptor for the TMTP-1 ligand (Fig. 6b).
The exposure of free TMTP-1 to PC-3 cells had an inhibitory effect
on DBP directed pEGFP-N1 delivery, with GFP ﬂuorescence
diminishing as inhibitor concentration was increased. These
results suggest that the TP is functional in both vectors and
utilized speciﬁc receptors to facilitate receptor-mediated endocy-
tosis through clathrin-coated vesicles (Rejman et al., 2004).
Preliminary mass spectrometry results have suggested that
aminopeptidase P, a GPI-linked membrane dipeptidese vascular
endothelial and lymphoid cell surface antigen, could be involved
but further examination is required to conﬁrm this (Yang et al.,
2008).
4. Conclusions
The major bottleneck of gene therapy is a cost-effective, safe
and efﬁcacious delivery system. Recombinant DNA technology
offers a potential solution for the production of multimeric-
targeted nanomedicines in a cost effective, stable and, simple
manner. Here, three systems were successfully synthesized, and
have a one-dimensional design (amino acid sequence) with three-
dimensional functionality. Using a reporter gene we have shown
both functionality and targeting potential. If the GALA is used in
these vectors, there must be a sufﬁcient cationic charge in other
motifs to compensate the anionicity. RMHT and RM3GT formed
cationic nanoparticles that speciﬁcally targeted PC-3 cells, exhib-
ited protection from serum, all with recoverable cell viability. The
functionality and molecular architecture of these DBP’s warrants
further investigation utilizing a cytotoxic gene to achieve
therapeutic outcomes for highly metastatic prostate cancer.
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